Skip to main content

Table 3 Description of adequacy of therapy **.

From: Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae

FACTOR

CASE FATALITY WITH FACTOR

CASE FATALITY WITHOUT FACTOR

RELATIVE RISK (95% CI)

P-VALUE

Adequate by t = 0

1/11 (9%)

15/68 (22%)

0.41 (0.06-2.81)

NS

Adequate by t = 8 hours

6/22 (27%)

10/57(18%)

1.55 (0.64-3.76)

0.09

Adequate by t = 24 hours

7/28 (25%)

9/51 (18%)

1.42 (0.59-3.39)

0.10

Adequate by t = 48 hours

9/42 (21%)

7/37 (18%)

1.13 (0.47-2.74)

NS

Adequate at t > 48 hours

3/33 (9%)

13/46 (28%)

0.32 (0.10-1.04)

NS

Never received adequate therapy

4/4 (100%)

12/75 (16%)

6.25 (3.72-10.5)

0.01

First Adequate Antibiotic Choice

    

Beta-lactam/Beta-lactamase inhibitor combination

6/28 (21%)

10/51 (20%)

1.09 (0.44-2.69)

NS

Carbapenem

4/30 (13%)

12/49 (24%)

0.54 (0.19-1.53)

NS

Fluoroquinolone

1/4 (25%)

15/75 (20%)

1.25 (0.22-7.24)

NS

Aminoglycoside

1/10 (10%)

15/69 (22%)

0.46 (0.07-3.11)

NS

Sulfa

1/3 (33%)

15/76 (20%)

1.69 (0.32-8.91)

NS

  1. ** Adequate therapy was defined by the receipt of a standard parenteral dose of an antimicrobial to which the organism was fully susceptible in vitro based on Clinical and Laboratory Standards Institute (CLSI) breakpoints or a standard oral dose of an antimicrobial with high bioavailability by this route, to which the organism was also fully susceptible.